Long-term follow-up shows that treatment with Empliciti plus pomalidomide and dexamethasone continues to significantly increase survival rates in patients with relapsed or refractory multiple myeloma, ...

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer. Adding Cabometyx ...

This episode, titled 'What It Takes to Make the Pathway: Clinical and Operational Criteria for Adding New Combinations in RRFL,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the ...

Patients who receive an add-on medication soon after a heart attack have a significantly better prognosis than those who receive it later, or not all, new research suggests. Patients who receive an ...

There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be ...